Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma
Bonnie K. Harrington(Michigan State University), William C. Kisseberth(The Ohio State University Wexner Medical Center)
Cited by 58
Related Papers
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890
Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis
|BMC Cancer|2017|46
Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines
|American Journal of Veterinary Research|2008|30
Biological activity of dihydroartemisinin in canine osteosarcoma cell lines
|American Journal of Veterinary Research|2008|27